Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ActiTrexx GmbH logo — ATreg - For a life without Transplant Rejection

ActiTrexx GmbH

ATreg - For a life without Transplant Rejection

Founded 2020 Germany Mainz, Germany 9 employees Series A Total: $3.50M Biotechnology

General Information

Company Name ActiTrexx GmbH
Founded Year 2020
Location Germany Mainz, Germany
Founders / Decision Makers
Team member
Employees 9
Industries Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with ActiTrexx GmbH. To contact ActiTrexx GmbH, visit actitrexx.de.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ActiTrexx GmbH compare?

A PDF of ActiTrexx GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ActiTrexx GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ActiTrexx GmbH

ActiTrexx GmbH is a biotech startup founded in 2020, with a vision to provide a curative cellular therapy to prevent inflammatory reactions in conditions such as GvHD, solid organ transplantation, and autoimmune diseases. The company's flagship product, ATreg, leverages regulatory T cells (Treg) to offer a safe and efficient treatment option for transplanted patients, with the potential to substantially decrease GvHD severity and related mortality. The management team of ActiTrexx GmbH brings together extensive experience in basic research, biotechnology, clinical application, and pharmaceutical development. Supported by a strong network of collaborators, advisors, key opinion leaders, and experienced managers, the company is well-positioned to advance its innovative cellular therapy. In March 2021, the company secured a significant €3.50M Series A investment from a group of notable investors, including HTGF | High-Tech Gruenderfonds, MediVentures, LBBW VC, Investitions- und Strukturbank Rheinland-Pfalz, underscoring the confidence in the potential of ActiTrexx's approach. With its headquarters in Mainz, Germany, ActiTrexx GmbH is poised to make impactful strides in the biotechnology industry.

Business keywords: biotech startup, cellular therapy, regulatory T cells, immune system, inflammatory reactions, GVHD, solid organ transplantation, autoimmune diseases, cell-based drug product, ATreg, clinical application, pharmaceutical development, Mainz, Germany, regenerative medicine, immunotherapy

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €3.50M 4
HTGF | High-Tech Gruenderfonds, MediVentures +2
02 Mar 2021

ActiTrexx GmbH Alternatives & Competitors

View All Alternatives
ActiTrexx GmbH vs
Enlivex Therapeutics (Nasdaq: ENLV)
Enlivex Therapeutics (Nasdaq: ENLV) Israel

Immune rebalancing

Post-IPO Equity
41 employees
Biotechnology, Health Care
ActiTrexx GmbH vs
Taiga Biotechnologies
Taiga Biotechnologies United States

Taiga Biotechnologies is a clinical stage biotechnology company focused on harnessing the power of t...

Seed
1 employees
Biotechnology, Health and Wellness
ActiTrexx GmbH vs
Q32 Bio Inc.
Q32 Bio Inc. United States

Revolutionizing the future of targeted immune therapeutics

28 employees
Biotechnology, Health Care
View all alternatives

FAQ About ActiTrexx GmbH

ATreg - For a life without Transplant Rejection
ActiTrexx GmbH was founded in 2020.
ActiTrexx GmbH is headquartered in Mainz, Germany.
ActiTrexx GmbH operates in Biotechnology. Its work centres on biotech startup, cellular therapy, regulatory T cells and immune system.
ActiTrexx GmbH has approximately 9 employees.
ActiTrexx GmbH has completed 1 funding round, raising a total of $3.50M. The latest funding stage is Series A.
Top alternatives and competitors to ActiTrexx GmbH include Enlivex Therapeutics (Nasdaq: ENLV), Taiga Biotechnologies, Q32 Bio Inc., Xenikos B.V., Tr1X. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ActiTrexx GmbH and Enlivex Therapeutics (Nasdaq: ENLV) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ActiTrexx GmbH, https://bouncewatch.com/company/actitrexx, updated 2 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout